The controversy of using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in COVID-19 patients.

Harky, Amer; Chor, Cheryl Yan Ting; Nixon, Henry; Jeilani, Milad

Harky, Amer; Chor, Cheryl Yan Ting; Nixon, Henry; Jeilani, Milad.

Harky A; Department of Cardiothoracic Surgery, Liverpool Heart and Chest, Liverpool, UK.
Chor CYT; Department of Congenital Cardiac Surgery, Alder Hey Children Hospital, Liverpool, UK.
Nixon H; Department of Integrative Biology, Faculty of Life Science, University of Liverpool, Liverpool, UK.
Jeilani M; Department of Medicine, St. George's Hospital Medical School, London, UK.

J Renin Angiotensin Aldosterone Syst ; 22(1): 1470320320987118, 2021.

Article in English | MEDLINE | ID: covidwho-1015808

Subject(s)

Angiotensin Receptor Antagonists/adverse effects; Angiotensin-Converting Enzyme Inhibitors/adverse effects; COVID-19/epidemiology; Hypertension/drug therapy; Hypertension/epidemiology; SARS-CoV-2; Age Factors; Angiotensin Receptor Antagonists/therapeutic use; Angiotensin-Converting Enzyme Inhibitors/therapeutic use; Black People; COVID-19/mortality; COVID-19/physiopathology; Comorbidity; Humans; Renin-Angiotensin System/physiology

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Angiotensin-Converting Enzyme Inhibitors / Angiotensin Receptor Antagonists / SARS-CoV-2 / COVID-19 / Hypertension Type of study: Observational study / Prognostic study Limits: Humans Language: English Journal: J Renin Angiotensin Aldosterone Syst Journal subject: Physiology Year: 2021 Document Type: Article Affiliation country: 1470320320987118

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google